Contact Us
Contact Us

At SCRI, we believe participation in a clinical trial should be the first option in fighting cancer, not the last.®

The Science of Collaboration Begins with Us

We partner with pharmaceutical and biotech companies, physicians and patients to advance the science of cancer treatments.

Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. Our contributions to pivotal research have helped to advance the majority of new cancer therapies approved by the FDA today.

 

Meet Our Leaders

250 plus

locations in 24 states

one in five

patients with cancer treated by SCRI and its affiliated sites

1300 plus

research physicians

Collaboration in Action

SCRI was the first to offer the revolutionary CRISPR/Cas9, a cellular gene-editing therapy, for Sickle Cell Disease.

Offering the groundbreaking CRISPR/Cas9 therapy required not only the expertise of a center that conducted transplant and cellular therapies, but also experienced research leaders and physicians who specialized in transplant therapies for disorders including Sickle Cell Disease. With these unique qualifications, combined with its robust research infrastructure, SCRI was equipped and prepared to care for patients with this innovative treatment and became the first site to open the clinical trial for Sickle Cell Disease.

 


This research helped lead to a significant breakthrough in the science of gene-editing, representing the first gene-editing technology approved by the U.S. Food & Drug Administration for the treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia shortly thereafter. Not only does SCRI’s contribution to this research give hope to people facing these disorders, but it will also continue to advance care and impact the future of research.

 

Collaborate with Us

Today’s Clinical Trials. Tomorrow’s Therapies.

SCRI is the only oncology research organization of its kind to offer end-to-end clinical trial site management, contract research services for biopharma and personalized medicine advisory services in one place:

  • Our Site Management Organization (SMO) delivers operational, regulatory and other centralized research support services for industry-sponsored and investigator-initiated trials.
  • SCRI Development Innovations, our global, full-service contract research organization (CRO) works in concert with SCRI's SMO, specializing in oncology clinical development services from first-in-human studies to regulatory approval.
  • Genospace, our fully-integrated precision medicine technology, powers our clinical trial offerings by ensuring we match the right therapy to the right patient at the right time.
Learn More About Our Offerings
1000 plus

trials actively enrolling

registered patients participating in trials yearly

first-in-human trials conducted since inception

Get to Know SCRI Leaders

Meet CEO, Dee Anna Smith

As CEO of SCRI, Dee Anna Smith leads the organization’s overall mission and vision to make a global impact on the next generation of cancer care.

");

Meet President, Howard “Skip” Burris, MD

Dr. Burris joined SCRI in 1997 to create the first drug development program outside of an academic setting and oversees all of SCRI’s clinical operations and research strategies. An oncology key opinion leader and former ASCO president, Dr. Burris has influenced new cancer treatment standards for more than 3 decades.

");

Meet CSO, David Spigel, MD

Dr. Spigel joined SCRI in 2003, and, as chief scientific officer, he oversees all scientific aspects of SCRI’s clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients.

");
top